Cardiome Pharma Corp. has received approval from South Africa’s Medicines Control Council (MCC) for Brinavess for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. “Cardiome is pleased with the approval of Brinavess in South Africa,” said Karim Lalji, Cardiome’s chief commercial officer. “We are committed to partnering Brinavess in this important pharmaceutical market as we continue to focus Cardiome’s direct sales efforts on...